We can't find the internet
Attempting to reconnect
25770.2 PFLS-LS
25770.2 PFLS-LS
Résumé
Development of a proprietary biomarker based companion diagnostic for identification and selection of cancer patients with disease driven by Notch pathway activation to be selected for treatment with Cellestia`s first-in-class pan NOTCH inhibitor and clinical development candidate drug CB-103.
Textes supplémentaires
Abstract
Development of a proprietary biomarker based companion diagnostic for identification and selection of cancer patients with disease driven by NOTCH pathway activation, for treatment with Cellestia`s first-in-class pan NOTCH inhibitor and clinical development candidate drug CB-103.
Participants
Rajwinder Lehal
Wirtschaftspartner
raj.lehal@cellestia.com
Cellestia Biotech AG CHE-162.364.457 Rajwinder Lehal Hochbergerstr. 60C 4057 Basel BS CH
Freddy Radtke
Kontaktperson
freddy.radtke@epfl.ch
EPFL SV ISREC UPRAD Life Science Faculty Freddy Radtke Station 19 1015 Lausanne VD CH
Détails du projet
- Office de recherche
- INNOSUISSE
- Statut du projet
- Abgeschlossen
- Type de projet
- Forschungsprojekt
- Date de début
- 2017-09-30
- Date de fin
- 2019-09-30
- Coûts totaux approuvés
- CHF 654452.35
- Section
- 20 Förderbereich Life Sciences
- Domaine politique NABS
- Industrielle Produktivität und Technologie
Disciplines de recherche
- T490 Biotechnology 100.0%